CRO WuXi AppTec ($WX) inked a deal to form a joint venture with AstraZeneca's ($AZN) MedImmune last week, and an analyst said the agreement will likely drive up front-end costs for the Chinese company. William Blair's John Kreger tells Outsourcing-Pharma that the CRO will have to ramp up its trial spending over the next few years, likely driving down earnings until the venture has a marketable drug. Report